{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:56:42Z","timestamp":1763755002619,"version":"3.45.0"},"reference-count":46,"publisher":"Oncology Nursing Society (ONS)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2020,4,1]]},"DOI":"10.1188\/20.cjon.199-204","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T11:18:12Z","timestamp":1584703092000},"page":"199-204","source":"Crossref","is-referenced-by-count":1,"title":["B-Cell Malignancies: The Use of Small Molecule Agents for Treatment and Management"],"prefix":"10.1188","volume":"24","author":[{"given":"Barbara","family":"Rogers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"1","unstructured":"AbbVie. (2019). Venclexta\u00ae (venetoclax) [Package insert]. https:\/\/www.rxabbvie.com\/pdf\/venclexta.pdf"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Ahn, I.E., Jerussi, T., Farooqui, M., Tian, X., Wiestner, A., & Gea-Banacloche, J. (2016). Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood, 128(15), 1940\u20131943. https:\/\/doi.org\/10.1182\/blood-2016-06-722991","DOI":"10.1182\/blood-2016-06-722991"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Ayyappan, S., & Maddocks, K. (2019). Novel and emerging therapies for B cell lymphoma. Journal of Hematology and Oncology, 12, 82. https:\/\/doi.org\/10.1186\/s13045-019-0752-3","DOI":"10.1186\/s13045-019-0752-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bauer, T.M., Patel, M.R., & Infante, J.R. (2015). Targeting PI3 kinase in cancer. Pharmacology and Therapeutics, 146, 53\u201360. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.09.006","DOI":"10.1016\/j.pharmthera.2014.09.006"},{"key":"5","unstructured":"Bayer Healthcare Pharmaceuticals. (2019). AliqopaTM (copanlisib) [Package insert]. http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Aliqopa_PI.pdf"},{"key":"6","unstructured":"BeiGene. (2019). BrukinsaTM (zanubrutinib) [Package insert]. https:\/\/www.brukinsa.com\/prescribing-information.pdf"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Borg, M.A., & Clemmons, A. (2017). Venetoclax: A novel treatment for patients with del(17p) chronic lymphocytic leukemia. Journal of the Advanced Practitioner in Oncology, 8, 647\u2013652. https:\/\/doi.org\/10.6004\/jadpro.2017.8.6.8","DOI":"10.6004\/jadpro.2017.8.6.8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Cheson, B.D., Enschede, S.H., Cerri, E., Desai, M., Potluri, J., Lamanna, N., & Tan, C. (2017). Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents. Oncologist, 22(11), 1283\u20131291. https:\/\/doi.org\/ 10.1634\/theoncologist.2017-0055","DOI":"10.1634\/theoncologist.2017-0055"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Coutr\u00e9, S.E., Barrientos, J.C., Brown, J.R., de Vos, S., Furman, R.R., Keating, M.J., . . . Zelenetz, A.D. (2015). Management of adverse events associated with idelalisib treatment: Expert panel opinion. Leukemia and Lymphoma, 56(10), 2779\u20132786. https:\/\/doi.org\/10.3109\/10428194.2015.1022770","DOI":"10.3109\/10428194.2015.1022770"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Crisci, S., Di Francia, R., Mele, S., Vitale, P., Ronga, G., DeFilippi, R., . . . Pinto, A. (2019). Overview of targeted drugs for mature B-cell non-Hodgkin lymphomas. Frontiers in Oncology, 9, 443. https:\/\/doi.org\/10.3389\/fonc.2019.00443","DOI":"10.3389\/fonc.2019.00443"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Dreyling, M., Santoro, A., Mollica, L., Lepp\u00e4, S., Follows, G., Lenz, G., . . . Zinzani, P.L. (2017). Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. Journal of Clinical Oncology, 35(35), 3898\u20133905. https:\/\/doi.org\/10.1200\/JCO.2017.75.4648","DOI":"10.1200\/JCO.2017.75.4648"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Esposito, A., Viale, G., & Curigliano, G. (2019). Safety, tolerability, and management of toxic effects of phosphatidylinositol 3-kinase inhibitor treatment in patients with cancer: A review. JAMA Oncology, 5(9), 1347\u20131354. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0034","DOI":"10.1001\/jamaoncol.2019.0034"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Flinn, I.W., O\u2019Brien, S., Kahl, B., Patel, M., Oki, Y., Foss, F., . . . Horwitz, S. (2018). Duvelisib, a novel oral dual inhibitor of PI3K-d, g, is clinically active in advanced hematologic malignancies. Blood, 131(8), 877\u2013887. https:\/\/doi.org\/10.1182\/blood-2017-05-786566","DOI":"10.1182\/blood-2017-05-786566"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Frustaci, A.M., Tedeschi, A., Deodato, M., Zamprogna, G., Cairoli, R., & Montillo, R. (2019). Duvelisib: A new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia. Future Oncology, 15(19), 2227\u20132239. https:\/\/doi.org\/10.2217\/fon-2018-0881","DOI":"10.2217\/fon-2018-0881"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Ghez, D., Calleja, A., Protin, C., Baron, M., Ledoux, M.P., Damaj, G., . . . Ysebaert, L. (2018). Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood, 131(17), 1955\u20131959. https:\/\/doi.org\/10.1182\/blood-2017-11-818286","DOI":"10.1182\/blood-2017-11-818286"},{"key":"16","unstructured":"Gilead Sciences. (2018). Zydelig\u00ae (idelalisib) [Package insert]. https:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/oncology\/zydelig\/zyd..."},{"key":"17","doi-asserted-by":"crossref","unstructured":"Giridhar, K.V., Shanafelt, T., Tosh, P.K., Parikh, S.A., & Call, T.G. (2017). Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors. Leukemia and Lymphoma, 58(8), 1973\u20131976. https:\/\/doi.org\/10.1080\/10428194.2016.1267352","DOI":"10.1080\/10428194.2016.1267352"},{"key":"18","unstructured":"Greenwell, I.B., Ip, A., & Cohen, J.B. (2017). PI3K inhibitors: Understanding toxicity mechanisms and management. Oncology, 31(11), 821\u2013828."},{"key":"19","doi-asserted-by":"crossref","unstructured":"Hammond, S.P., Chen, K., Pandit, A., Davids, M.S., Issa, N.C., & Marty, F.M. (2018). Risk of hepatitis B virus reactivations in patients treated with ibrutinib. Blood, 131(17), 1987\u20131989. https:\/\/doi.org\/10.1182\/blood-2018-01-826495","DOI":"10.1182\/blood-2018-01-826495"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Heldt Manica, L.A., & Cohen, P.R. (2017). Ibrutinib-associated nail plate abnormalities: Case reports and review. Drug Safety\u2014Case Report, 4, 15. https:\/\/doi.org\/10.1007\/s40800-017-0060-1","DOI":"10.1007\/s40800-017-0060-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Khan, M., & Siddiqi, T. (2018). Targeted therapies in CLL: Monotherapy versus combination approaches. Current Hematologic Malignancy Reports, 13, 525\u2013533. https:\/\/doi.org\/10.1007\/s11899-018-0481-7","DOI":"10.1007\/s11899-018-0481-7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Kim, H.O. (2019). Development of BTK inhibitors for the treatment of B-cell malignancies. Archives of Pharmacal Research, 42(2), 171\u2013181. https:\/\/doi.org\/ 10.1007\/s12272-019-01124-1","DOI":"10.1007\/s12272-019-01124-1"},{"key":"23","doi-asserted-by":"crossref","unstructured":"King, A.C., Peterson, T.J., Horvat, T.Z., Rodriguez, M., & Tang, L.A. (2017). Venetoclax: A first-in-class oral BCL-2 inhibitor for the management of lymphoid malignancies. Annals of Pharmacotherapy, 51(5), 410\u2013416. https:\/\/doi.org\/10.1177\/1060028016685803","DOI":"10.1177\/1060028016685803"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Knight, Z.A., Gonzalez, B., Feldman, M.E., Zunder, E.R., Goldenberg, D.D., Williams, O., . . . Shokat, K.M. (2006). A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell, 125(4), 733\u2013747.","DOI":"10.1016\/j.cell.2006.03.035"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Kurtin, S.E., & McBride, A. (2017). Small molecules in chronic lymphocytic leukemia: Novel targets, new challenges. Journal of the Advanced Practitioner in Oncology, 8(Suppl. 7), 55\u201369. https:\/\/doi.org\/10.6004\/jadpro.2017.8.7.16","DOI":"10.6004\/jadpro.2017.8.7.16"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Levy, I., Polliack, A., & Tadmor, T. (2019). Five ibrutinib-associated side effects that all clinicians should be aware of. Acta Haematologica, 141(4), 254\u2013255. https:\/\/doi.org\/10.1159\/000497356","DOI":"10.1159\/000497356"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Mato, A.R., Hill, B.T., Lamanna, N., Barr, P.M., Ujjani, C.S., Brander, D.M., . . . Nabhan, C. (2017). Optimal sequencing of ibrutinib, idelalisib and venetoclax in chronic lymphocytic leukemia: Results from a multicenter study of 683 patients. Annals of Oncology, 28(5), 1050\u20131056. https:\/\/doi.org\/10.1093\/annonc\/mdx031","DOI":"10.1093\/annonc\/mdx031"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Mato, A.R., Thompson, M., Allan, J.N., Brander, D.M., Pagel, J.M., Ujjani, C.S., . . . Nabhan, C. (2018). Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica, 103(9), 1511\u20131517. https:\/\/doi.org\/10.3324\/haematol.2018.193615","DOI":"10.3324\/haematol.2018.193615"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Mensah, F., Blaize, J.P., & Bryan, L. (2018). Spotlight on copanlisib and its potential in the treatment of relapsed\/refractory follicular lymphoma: Evidence to date. OncoTargets and Therapy, 11, 4817\u20134827. https:\/\/doi.org\/10.2147\/OTT.S142264","DOI":"10.2147\/OTT.S142264"},{"key":"30","unstructured":"National Comprehensive Cancer Network. (2019). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma [v.1.2020]. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/waldenstroms.pdf"},{"key":"31","unstructured":"National Comprehensive Cancer Network. (2020a). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): B-cell lymphomas [v.1.2020]. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf"},{"key":"32","unstructured":"National Comprehensive Cancer Network. (2020b). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Chronic lymphocytic leukemia\/small lymphocytic lymphoma [v.4.2020]. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Owen, C., Berinstein, N.L., Christofides, A., & Sehn, L.H. (2019). Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Current Oncology, 26(2), e233\u2013e240. https:\/\/doi.org\/10.3747\/co.26.4345","DOI":"10.3747\/co.26.4345"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Pauls, S.D., Lafarge, S.T., Landego, I., Zhang, T., & Marshall, A.J. (2012). The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: Activation, mechanisms, regulation, and impact on cellular functions. Frontiers in Immunology, 3, 224.","DOI":"10.3389\/fimmu.2012.00224"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Paydas, S. (2019). Management of adverse effects\/toxicity of ibrutinib. Critical Reviews in Oncology\/Hematology, 136, 56\u201363. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.02.001","DOI":"10.1016\/j.critrevonc.2019.02.001"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Robak, T. (2015). BCL-2 inhibitors for chronic lymphocytic leukemia. Journal of Leukemia, 3(3), 1000e114. https:\/\/doi.org\/10.4172\/2329-6917.1000e114","DOI":"10.4172\/2329-6917.1000e114"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Roberts, A.W., Davids, M.S., Pagel, J.M., Kahl, B.S., Puvvada, S.D., Gerecitano, J.F., . . . Seymour, J.F. (2016). Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 374(4), 311\u2013322. https:\/\/doi.org\/10.1056\/nejmoa1513257","DOI":"10.1056\/NEJMoa1513257"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Roeker, L.E., Fox, C.P., Eyre, T.A., Brander, D.M., Allan, J.N., Schuster, S.J., . . . Mato, A.R. (2019). Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice. Clinical Cancer Research, 25(14), 4264\u20134270. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-0361","DOI":"10.1158\/1078-0432.CCR-19-0361"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Shanafelt, T.D., Parikh, S.A., Noseworthy, P.A., Goede, V., Chaffee, K.G., Bahlo, J., . . . Kay, N.E. (2017). Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leukemia and Lymphoma, 58(7), 1630\u20131639. https:\/\/doi.org\/10.1080\/10428194.2016.1257795","DOI":"10.1080\/10428194.2016.1257795"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Sollena, P., Mannino, M., Laurenti, L., De Simone, C., & Peris, K. (2019). Ibrutinib-associated palmo-plantar fissures in a patient with chronic lymphocytic leukaemia: A novel cutaneous adverse event. Journal of the European Academy of Dermatology and Venerology, 33(9). https:\/\/doi.org\/10.1111\/jdv.15632","DOI":"10.1111\/jdv.15632"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., . . . Jaffe, E.S. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127(20), 2375\u20132390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"42","unstructured":"Verastem. (2018). Copiktra\u00ae (duvelisib) [Package insert]. https:\/\/www.verastem.com\/wp-content\/uploads\/2018\/08\/prescribing-informat..."},{"key":"43","doi-asserted-by":"crossref","unstructured":"Wang, M., Rule, S., Zinzani, P.L., Goy, A., Casasnovas, O., Smith, S.D., . . . Jurczak, W. (2018). Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicenter, phase 2 trial. Lancet, 391(10121), 659\u2013667. https:\/\/doi.org\/10.1016\/S0140-6736(17)33108-2","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Wilson, P.A., & Melville, K. (2019). Disseminated cryptococcal infection in a patient receiving acalabrutinib for chronic lymphocytic leukemia. Infectious Diseases in Clinical Practice, 27(3), 160\u2013162. https:\/\/doi.org\/10.1097\/ipc.0000000000000722","DOI":"10.1097\/IPC.0000000000000722"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Youle, R.J., & Strasser, A. (2008). The BCL-2 protein family: Opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology, 9, 47\u201359.","DOI":"10.1038\/nrm2308"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Zhang, S.Q., Smith, S.M., Zhang, S.Y., & Wang, Y.L. (2015). Mechanism of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. British Journal of Haematology, 170(4), 445\u2013456.","DOI":"10.1111\/bjh.13427"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/24\/2\/b-cell-malignancies-use-small-molecule-agents-treatment-and-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:50:22Z","timestamp":1763754622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/24\/2\/b-cell-malignancies-use-small-molecule-agents-treatment-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1188\/20.cjon.199-204","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}